Schweitzer, M. L.
Stengel, B.
Legrand, K.
Briançon, S.
Jacquelinet, C.
Combe, C.
Fouque, D.
Massy, Z. A.
Laville, M.
Frimat, L.
Ayav, C.
Funding for this research was provided by:
Agence Nationale de la Recherche
Amgen
Baxter International
Fresenius Medical care
GlaxoSmithKline foundation
Merck Sharp and Dohme
Lilly France
Otsuka Pharmaceutical
Sanofi-Genzyme
Direction Générale de l’offre de Soins (FR), PHRC-N
Vifor Fresenius
Article History
Accepted: 11 January 2019
First Online: 18 January 2019
Compliance with ethical standards
:
: CKD-REIN is supported by a public–private partnership with funding from 9 pharmaceutical companies as listed above. All authors declare that they have no relevant financial interests.
: All legal authorizations were obtained including those from the <i>Comité consultatif sur le traitement de l’information en matière de recherche dans le domaine de la santé</i> (CCTIRS No 12.360), the <i>Commission nationale de l’informatique et des libertés</i> (CNIL No DR-2012-469), and the <i>Comité de protection des personnes</i> IDF VII (CPP No IDRCB 2012-A00902-41). CKD-REIN biological collection is registered in the management application of the <i>COnservation D’Eléments du COrps Humain</i> (CODECOCH No-2012-1624). The <i>Institut national de la santé et de la recherche médicale</i> (Inserm) Institutional Review Board approved the study protocol (IRB00003888).